News articles about Baxter International (NYSE:BAX) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Baxter International earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave press coverage about the medical instruments supplier an impact score of 46.463536222025 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Bafana Bafana coach Baxter to name final Cosafa Cup squad on Monday (timeslive.co.za)
- Baxter to Present at the Goldman Sachs Healthcare Conference (finance.yahoo.com)
- Insider Selling: Baxter International (BAX) SVP Sells 20,000 Shares of Stock (americanbankingnews.com)
- Baxter Is Quickly Rebuilding Its Solid Dividend (seekingalpha.com)
- Baxter International (BAX) Lifted to Buy at Zacks Investment Research (americanbankingnews.com)
A number of equities analysts have recently weighed in on the company. Zacks Investment Research cut Baxter International from a “buy” rating to a “hold” rating in a report on Wednesday. Citigroup boosted their price target on Baxter International from $66.00 to $70.00 and gave the stock a “neutral” rating in a report on Tuesday, February 6th. Deutsche Bank raised Baxter International from a “hold” rating to a “buy” rating and set a $80.00 price target for the company in a report on Tuesday, February 20th. Royal Bank of Canada reissued a “hold” rating and issued a $72.00 price target on shares of Baxter International in a report on Friday, February 2nd. Finally, ValuEngine cut Baxter International from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Six investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Baxter International presently has a consensus rating of “Buy” and an average price target of $72.47.
Shares of NYSE:BAX traded down $0.05 during midday trading on Friday, reaching $70.60. The company’s stock had a trading volume of 3,478,358 shares, compared to its average volume of 3,182,164. The company has a market cap of $37.88 billion, a P/E ratio of 28.47, a P/E/G ratio of 1.83 and a beta of 0.81. The company has a quick ratio of 2.03, a current ratio of 2.63 and a debt-to-equity ratio of 0.39. Baxter International has a 1 year low of $56.82 and a 1 year high of $72.58.
Baxter International (NYSE:BAX) last announced its quarterly earnings data on Thursday, April 26th. The medical instruments supplier reported $0.70 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.08. The business had revenue of $2.68 billion during the quarter, compared to the consensus estimate of $2.62 billion. Baxter International had a return on equity of 15.70% and a net margin of 7.75%. The business’s revenue for the quarter was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.58 earnings per share. sell-side analysts expect that Baxter International will post 2.89 earnings per share for the current fiscal year.
Baxter International announced that its Board of Directors has approved a share buyback plan on Tuesday, February 20th that allows the company to repurchase $1.50 billion in shares. This repurchase authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 2nd. Stockholders of record on Friday, June 1st will be given a $0.19 dividend. The ex-dividend date of this dividend is Thursday, May 31st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.08%. This is an increase from Baxter International’s previous quarterly dividend of $0.16. Baxter International’s payout ratio is currently 25.81%.
In other Baxter International news, SVP Brik V. Eyre sold 20,000 shares of the business’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $70.57, for a total transaction of $1,411,400.00. Following the completion of the sale, the senior vice president now owns 85,115 shares of the company’s stock, valued at $6,006,565.55. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Peter S. Hellman sold 3,760 shares of the business’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $64.74, for a total value of $243,422.40. Following the sale, the director now directly owns 25,522 shares of the company’s stock, valued at approximately $1,652,294.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,500 shares of company stock valued at $3,194,912. 0.05% of the stock is owned by company insiders.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.